The pharmacological inhibition of β−catenin activation by the novel tankyrase inhibitor BAY6060, but not the inhibition of PI3K activity by BAY1082439 alone (Hill et al., 2017), can also significantly reduce the number of HAVCR2high LSCs in vivo in late-stage T-ALL (Figure 8G). This evidence concerns the gene TNKS and acute lymphoblastic leukemia.